May. 27 at 1:32 PM
🚨 Nobody is talking about
$CUE, and that's about to change
🔬 WHAT THEY DO:
Precision immunotherapy: instead of broadly nuking the immune system, their platform targets ONLY the specific cells causing disease. Scalpel, not sledgehammer.
Pipeline spans cancer, autoimmune & allergy. Three massive markets.
📌 KEY POINTS:
✅ Boehringer Ingelheim deal worth up to
$345M in milestones -
$7.5M already earned in April 2026. Big pharma validates.
✅ Revenue up 14x YoY. Net loss cut in half. Financials moving in the right direction.
✅ CUE-221 - ONE dose suppressed IgE for 12+ weeks in Phase 1. Phase 2 data due H2 2026.
✅ New CEO founded her last company, took it public at
$2 B+. Previously AbbVie, Gilead & Amgen.
✅
$27.6M just raised to fund the pipeline !
CommunicatedDisclaimer:http://stockresearchtoday.com/cue/
